Pure Peptides Lab Ltd is registered in England & Wales, company number 16876166 .
Email us now:
Compound deep-dive
Semaglutide explained: the GLP-1 receptor agonist that defined the modern era.
A 31-amino-acid synthetic peptide developed by Novo Nordisk. Three small engineering changes to the native human GLP-1 backbone produced an 11000-fold half-life increase. The molecule that brought the once-weekly GLP-1 era from theory to mass-market reality, and the benchmark every later compound (tirzepatide, retatrutide) is measured against.
Semaglutide Research Overview
TL;DR. Semaglutide is a 31-amino-acid synthetic peptide that activates the GLP-1 receptor. It is built on the native human GLP-1 (7-37) backbone with three engineered modifications.
- Aib at position 8 for DPP-4 resistance.
- Arg substitution at position 34 to eliminate a competing acylation site.
- C18 fatty diacid attached to Lys26 via gamma-Glu plus two AEEA spacers to enhance albumin binding.
Pharmacokinetics
The average molecular weight is 4113.58 g/mol. Its effective half-life is approximately 165 hours, supporting once-weekly subcutaneous dosing.
Clinical Research
The STEP-1 trial (Wilding et al., NEJM 2021) demonstrated a 14.9% reduction in body weight using 2.4 mg weekly over 68 weeks.
The SELECT trial (Lincoff et al., NEJM 2023) became the first study showing a GLP-1 receptor agonist reduced cardiovascular events in individuals without diabetes, achieving approximately a 20% reduction in MACE.
Laboratory Verification
A high-quality research-grade batch should demonstrate:
- Single-peak HPLC chromatogram with 99%+ purity.
- Mass spectrometry confirmation of 4113.58 g/mol.
- Uniform porous white lyophilized cake.
Research Use Only.
This material is intended exclusively for laboratory research and is not a substitute for prescription medications such as Ozempic®, Wegovy®, or Rybelsus®.
What Semaglutide actually is
Semaglutide is a long-acting analogue of human glucagon-like peptide-1, the gut hormone released after a meal that drives a glucose-dependent insulin response in the pancreatic beta cells along with a wider set of effects on satiety, gastric emptying, and adipose-tissue function. The native human GLP-1 peptide is biologically powerful but pharmacologically useless on its own: it has a circulating half-life of around 90 seconds, because the dipeptidyl peptidase-4 (DPP-4) enzyme cleaves it almost as fast as it is released and the kidneys clear what remains.
Semaglutide solves both problems with three small changes to the native GLP-1(7-37) sequence. The molecule was discovered and characterised at Novo Nordisk by Lotte Bjerre Knudsen and her team across the early 2010s, and the foundational publication is Lau et al., “Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide” (J. Med. Chem. 2015). Three modifications, one engineering goal: stop the molecule being cleaved, slow the molecule being cleared.
| Length | 31 amino acids (with C-terminal glycine) |
| Average MW | 4113.58 g/mol |
| Modification 1 | Aib at position 8 (alpha-aminoisobutyric acid replaces native Ala) – blocks DPP-4 cleavage |
| Modification 2 | Arg at position 34 (replaces native Lys) – removes competing acylation site |
| Modification 3 | C18 fatty diacid attached at Lys26 via gamma-Glu plus 2 x AEEA spacer – drives albumin binding |
| Receptor profile | Single-target GLP-1 receptor agonist (no GIP, no glucagon) |
| Half-life | ~165 hours (~7 days), supports once-weekly subcutaneous administration |
| Lyophilised stability | 24+ months at 2–8 °C, sealed and protected from light |
| Branded prescription products | Ozempic (subcut, T2D), Wegovy (subcut, obesity), Rybelsus (oral, T2D) |
The three engineering changes that built the molecule
How three small substitutions produced an 11000-fold half-life jump.
Native GLP-1: cleaved by DPP-4 at the Ala8 – Glu9 bond within seconds of release, half-life around 90 seconds. Change 1, position 8 Ala becomes Aib. Aib (alpha-aminoisobutyric acid) is a non-natural amino acid with a sterically hindered alpha carbon that DPP-4 simply does not recognise. The cleavage step is gone.
That alone takes you from seconds to minutes, but the kidneys still filter the molecule out within hours. Change 2, attach a long fatty diacid to Lys26 via a small linker (gamma-Glu plus 2 x AEEA) so the molecule binds reversibly to serum albumin. Albumin is the most abundant protein in plasma. A peptide that sticks to albumin clears at roughly the rate albumin clears, which is days, not hours.
The fatty acid wants to attach to any free lysine side chain during synthesis, so without a third change you would get a mixture of Lys26-acylated and Lys34-acylated product. Change 3, swap Lys34 for Arg. Same backbone shape, but the side chain is no longer a target for the acylation chemistry. The synthesis is now clean and the final molecule is a defined, single-modification compound.
End result: native GLP-1 half-life ~90 seconds, semaglutide half-life ~165 hours. About 6600-fold longer in the bloodstream from three deliberate residue choices. Modern long-acting peptide design in one molecule.
The STEP and SELECT trial data
The Phase 3 programme has been one of the most consequential metabolic-research trial sets of the last decade. Two parallel arcs.
SUSTAIN (type 2 diabetes)
Seven trials (SUSTAIN-1 through 7+) in adults with type-2 diabetes. Across the series, semaglutide produced larger reductions in HbA1c and body weight than placebo, dulaglutide, exenatide ER and insulin glargine at matched dose comparisons. SUSTAIN-6 (Marso et al., NEJM 2016) was the first cardiovascular outcomes trial in the programme and showed non-inferiority on major adverse cardiovascular events.
STEP (obesity, no diabetes required)
The pivotal obesity trial, STEP-1, was published as Wilding et al., NEJM 2021, PMID 33567185. 1961 adults with obesity (mean BMI 37.9) but without type-2 diabetes were randomised to placebo or semaglutide 2.4 mg weekly for 68 weeks.
| Trial | Population | Duration | Body-weight change at endpoint |
|---|---|---|---|
| STEP-1 | Adults with obesity, no T2D | 68 weeks | −14.9 % (vs −2.4 % placebo) |
| STEP-2 | Adults with T2D + obesity | 68 weeks | −9.6 % (vs −3.4 % placebo) |
| STEP-3 | Adults with obesity + intensive behavioural therapy | 68 weeks | −16.0 % (vs −5.7 % placebo) |
| STEP-5 | Adults with obesity, no T2D | 104 weeks | −15.2 % sustained |
| STEP-8 | Head-to-head vs liraglutide | 68 weeks | Beat liraglutide on every primary endpoint |
SELECT (cardiovascular outcomes in obesity, no diabetes)
The single most important data point published on semaglutide outside diabetes was the SELECT trial, Lincoff et al., NEJM 2023, PMID 37962078. 17604 adults with overweight or obesity plus established cardiovascular disease but without type-2 diabetes were randomised to placebo or semaglutide 2.4 mg weekly. After a mean follow-up of 39.8 months, the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) was reduced by 20 percent in the semaglutide arm.
SELECT was the first demonstration in the published trial literature that a GLP-1 receptor agonist reduces cardiovascular events in a non-diabetic population. The 2024 expansion of the FDA Wegovy label to include cardiovascular risk reduction in adults with established CVD plus overweight or obesity rests on this data.
The branded products
- Ozempic (subcutaneous injection, type-2 diabetes). FDA approved December 2017, MHRA 2018.
- Rybelsus (oral once-daily tablet, type-2 diabetes). FDA approved September 2019. The first oral GLP-1 receptor agonist to reach market.
- Wegovy (subcutaneous injection, chronic weight management). FDA approved June 2021 for adults, December 2022 for adolescents 12+. MHRA 2021.
What to look for on the Certificate of Analysis
If you’ve read our walk-through of a Janoshik HPLC report, the standard structure applies. For semaglutide specifically:
1. A single tall peak on the reversed-phase HPLC chromatogram
One dominant peak at the semaglutide retention time, a flat baseline elsewhere, 99%+ purity in the analytical summary. The semaglutide market has been awash with counterfeit and underdosed material since the global Ozempic and Wegovy supply shortages of 2022 and 2023. The trace itself matters more than the quoted percentage.
2. Mass spectrometry confirmation of the 4113.58 g/mol mass
Semaglutide is large enough that electrospray mass spectra show multiply-charged species rather than a single intact molecular ion. The typical positive-ion charge states are [M+3H]3+ at m/z 1372.2, [M+4H]4+ at m/z 1029.4, [M+5H]5+ at m/z 823.7, and [M+6H]6+ at m/z 686.6. A real spectrum from Janoshik or any competent peptide-analysis lab will show a characteristic ladder of these charge states with the masses cross-summable back to 4113.58 g/mol average.
3. The Janoshik verification key resolves on their portal
Every Janoshik certificate carries a short alphanumeric verification key. That key plus the task ID printed on the certificate can be cross-referenced on the issuing lab’s public records. A real semaglutide batch resolves; a fabricated COA does not. Cross-check it yourself.
Storage and handling at your bench
- Refrigerate at 2–8 °C in the original sealed amber-glass vial. Semaglutide is stable for 24 months or more in the lyophilised state when kept dry, sealed, and protected from light.
- Reconstitute with bacteriostatic water by adding the water slowly down the inside wall of the vial and gently swirling (not shaking, never vortexing) until the cake fully dissolves. The resulting solution should be clear and colourless.
- Reconstituted shelf life is shorter than the lyophilised form. The published preclinical analytical literature commonly references stability over a window of four to six weeks under refrigeration.
- Avoid freeze-thaw cycles on the reconstituted solution. The lipid modification makes semaglutide micelle-prone in solution and repeated freeze-thaw is the most common cause of measurable activity loss.
- Ship and store in amber glass. Less photolabile than copper-coordinated peptides like GHK-Cu, but cold-chain amber-glass is the right default for any modern long-acting lipopeptide.
Common red flags when sourcing semaglutide
Walk-away signals when buying semaglutide
- The lyophilised cake in the supplier’s product photos is yellowed, cream-coloured, or shown as a heap of loose granular powder rather than a uniform porous white cake. Semaglutide done correctly produces a clean white puck.
- No batch-specific Certificate of Analysis included with the order. The semaglutide market is the second-most-counterfeited peptide segment globally (after tirzepatide); a generic “we test our products” line on the website is not the same as a per-batch COA tied to the vial in your hand.
- The COA carries no verification key, or the key does not resolve on the issuing lab’s public portal.
- The chromatogram (if shown) has multiple peaks of comparable height. Semaglutide synthesis at 99%+ produces a single dominant peak with minor impurities, not a cluster of near-equal peaks.
- Mass-spectrometry data is absent or shows only one of the multiply-charged species in isolation. A real semaglutide spectrum has the multi-charge-state ladder.
- The supplier markets “semaglutide” oral capsules that claim to match Rybelsus pharmacokinetics. Rybelsus is a complex formulation built around a permeation enhancer (SNAC) and is not reproducible by simply encapsulating research-grade powder.
- Pricing far below the broader market rate. Semaglutide is not a cheap molecule to synthesise correctly to 99%+ purity. A vial at a fraction of the going rate is, more often than not, a vial of an older, cheaper GLP-1 analogue with a semaglutide label on it, or an underdosed product.
- Vial label has no batch number, no fill weight, or no manufacturer identifier.
Where this fits in the metabolic-research family
Semaglutide is the first generation of the long-acting GLP-1 architecture; How to Read a Janoshik HPLC Report | Peptide Purity Guide is the second generation (dual GIP plus GLP-1); retatrutide is the third (trinity GIP plus GLP-1 plus glucagon). The receptor footprint widens with each generation and the published trial endpoints scale roughly with that footprint. Our side-by-side write-ups cover the trade-offs:
- Semaglutide vs Retatrutide – single-target vs trinity agonist
- Tirzepatide vs Semaglutide – dual vs single agonist
- Semaglutide vs Liraglutide – once-weekly vs once-daily, two generations of the same architecture
What we supply
We stock semaglutide as a lyophilised cake in 5mg, 10mg and 20mg amber-glass vials, plus a pre-filled pen format in matching dose strengths, independently HPLC-verified by Janoshik Analytical to 99%+ purity. The Janoshik Certificate of Analysis ships in the box with every order where one is available for the current batch, and the report is also published on our Purity page for independent reference. The product page with current pricing, the integrated dose calculator (built around the STEP-1 0.25 / 0.5 / 1 / 1.7 / 2.4 mg weekly titration ladder), the research-protocol tabs, and the BAC-water option is at /peptides/semaglutide.html.
Important regulatory note. Novo Nordisk’s branded semaglutide products are licensed in the UK as Ozempic (type-2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral type-2 diabetes). Those licensed products are prescription-only medicines administered or self-administered under prescriber supervision and dispensed by a registered pharmacy under the regulatory framework that applies to MHRA-authorised medicines. Pure Peptides Lab Ltd supplies semaglutide as a research-grade reference reagent for laboratory and in-vitro research only. Our product is NOT a substitute for, equivalent to, or marketed as a generic of Ozempic, Wegovy or Rybelsus. We do not provide therapeutic claims, dosing guidance, administration protocols, or any content relating to human or veterinary use. If a clinician has prescribed any of those branded products for you, the licensed pharmacy product is the correct route.
Research use only. The compound information described above is drawn from peer-reviewed analytical and clinical literature and is provided for laboratory and in-vitro research context.